Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?

  title={Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?},
  author={Zoran Milan Pavlovic},
Cannabis has a long history in Central and South Asia, as it was used to produce hemp fibre for rope, clothing and paper, but was also consumed both for recreational and medicinal purposes. The two major neuro active components in cannabis are the psychoactive Δ9-tetrahydro-cannabinol (Δ9-THC) and the non-psychoactive cannabidiol (CBD). Recent years have seen a resurgence in interest in the therapeutic potential of compounds derived from cannabis, due to significant advances in our… 


Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
Atypical location of cannabinoid receptors in white matter areas during rat brain development
The results indicated that specific binding for cannabinoid receptors can be detected in the brain of rat fetuses at GD21 in the classic areas that contain these receptors in adulthood, and the existence of a transient period of the brain development in the rat, around the last days of the fetal period and the first days of postnatal life, in which CB1 receptors appear located in neuronal fiber‐enriched areas.
Molecular mechanisms of fragile X syndrome: a twenty-year perspective.
Studies continue to refine the understanding of FMRP's role in synaptic plasticity and to uncover new functions of this protein, which have illuminated therapeutic approaches for FXS.
More surprises lying ahead. The endocannabinoids keep us guessing
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
Pretreatment with the cannabinoid antagonist SR141716A enhanced the stimulation of motor behavior elicited by systemic administration of quinpirole, suggesting that the endocannabinoid system may act as an inhibitory feedback mechanism countering dopamine-induced facilitation of motor activity.
The mGluR theory of fragile X mental retardation
The CB1 Cannabinoid Receptor Is the Major Cannabinoid Receptor at Excitatory Presynaptic Sites in the Hippocampus and Cerebellum
Electrophysiological and immunohistochemical data and morphological data indicate that CB1 is responsible for cannabinoid-dependent suppression of excitatory transmission in the hippocampus and cerebellum.
Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
Research regarding dysregulation of neurotransmitter systems in FXS, including the metabotropic glutamate receptor (mGluR)1/5 pathway and γ aminobutyric acid (GABA)A pathways, have led to new targeted treatments for FXS and preliminary evidence suggests that these new targeted treatment will also be beneficial in non-fragile X forms of autism.
Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats
Data show that increased anandamide signaling in the amygdala and NAc augments social play, and identify the BLA as a prominent site of action for endocannabinoids to modulate the rewarding properties of social interactions in adolescent rats.
Neuroglial activation and neuroinflammation in the brain of patients with autism
It is indicated that innate neuroimmune reactions play a pathogenic role in an undefined proportion of autistic patients, suggesting that future therapies might involve modifying neuroglial responses in the brain.